Mankind Pharma and Daewoong Pharma collaborates for COVID-19 Treatment


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ mankind-pharma-daewoong-pharma-provide-innovative-treatment-option-coronavirus
Mankind Pharma and Daewoong Pharmaceutical announce initiation of phase 1 clinical trial on a ‘Novel’ formulation of Niclosamide (DWRX2003) for COVID-19 treatment

Daewoong Pharmaceutical Co., Ltd., South Korea (through its subsidiary, Daewoong Pharmaceutical India Pvt. Ltd.) and Mankind Pharma, fastest-growing Indian Pharmaceutical Company, have collaborated for conducting Phase I clinical trial of a long-acting intramuscular formulation of Niclosamide. The trial is designed towards addressing the need for a science-based investigation on this new formulation “Niclosamide (DWRX2003)” based on encouraging preclinical evidence for the treatment of COVID-19.

Niclosamide (DWRX2003) is already in clinical use as an anthelmintic; however, the current formulation is expected to be a long-acting variant for this alternate clinical indication. It is also expected to circumvent the downside of oral administration.

In vitro, Niclosamide (DWRX2003) was found to be 40, 26 & 15 times more potent than Remdesivir, Chloroquine & Ciclesonide respectively for its anti-viral action against SARS-CoV-2 virus. Also, the injectable intramuscular (IM) formulation of Niclosamide successfully removed the virus from lungs in animal tests, thereby countering viral infection, besides preventing cytokine storm which is the major cause of mortality in moderate to severe cases of COVID-19.

Through intensive motivated research, Daewoong researchers worked on quick development of the formulation to have reached the stage of “First-in-Human” evaluation, successful completion of which would immensely facilitate COVID-19 disease treatment.

Mr Arjun Juneja, COO, Mankind Pharma Ltd. commented “We are continuously evaluating various target products for the treatment of Covid-19 in support to national response to COVID-19 pandemic.

In continuation to Mankind Pharma's vision to serve society by bringing quality and affordable medicine. We are excited to collaborate with Daewoong Pharmaceutical Co., Ltd. to bring the Novel formulation of Niclosamide (DWRX2003) for the treatment of COVID-19 patients in India. We believe that the product would provide for a safe and effective alternative to patients suffering from this disease”.

We are already working on other unrelated COVID-19 focussed programs, in tandem with community and society as part of our Corporate Social Responsibility initiatives.

Sengho Jeon, CEO of Daewoong Pharmaceutical commented “Through the development of candidates for COVID-19 treatments such as Nicosamide, which Daewoong Pharmaceutical is currently developing, we expect to provide an innovative treatment option for patients suffering from COVID-19.

I believe Mankind Pharma is one of the best partners to accelerate the clinical development and supply of DWRX2003 for India"

Tags : #MankindPharma #DaewoongPharmaceutical #ArjunJuneja #SenghoJeon #Remdesivir

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026